MiNK Therapeutics (INKT) Net earnings per share growth forecast for next year

Symbol and logo of brand MiNK (INKT)

The scalability of MiNK Therapeutics, Inc. (INKT) cell platforms enables the mass delivery of affordable therapies. The current consensus EPS growth forecast for next year reflects expectations fixed at 32.60. Strong pricing power in the solid tumor segment and patent protection of iNKT technologies create a robust barrier to entry for competitors, ensuring the company's long-term dominance in immuno-oncology.

INKT - MiNK Earnings growth forecast for next year over the range 07/04/2022 - 11/18/2026

Metric breakdowns and analytics for MiNK (INKT)

- price and consensus price forecast:
Analysis of all company metrics:MiNK
Core merchandise of MiNK Therapeutics Inc.

When screening issuer reliability, this indicator allows for an assessment of the consensus forecast for future profitability through the dynamics of expected earnings per share. The metric measures the rate of change in net income, determining fair pricing multiples and business value equilibrium points. For MiNK Therapeutics, Inc. (INKT), with its patent potential in cancer therapy, the earnings growth rate model for the coming year reflects market confidence in the commercialization of its innovations.

Direct competitors

Net earnings per share growth forecast for next year immunitybio.com|Expected earnings per share growth for next year immunocore.com (IMCR)|Net earnings per share growth forecast for next year Janux Therapeutics Inc (JANX)|Expected earnings per share growth for next year Arcus Bio RCUS|Zymeworks Inc - Expected earnings per share growth for next year|Earnings growth forecast for next year Tango Therapeutics Corp TNGX|IOVA - Net earnings per share growth forecast for next year|IMTX (immatics.com) - Projected earnings per share growth rate for next year|Xencor Inc. (XNCR) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Compass Bio (CMPX)|Expected earnings per share growth for next year REPL|LYEL - Net earnings per one share growth forecast for next year|Expected earnings per share growth for next year IPHA (Innate Pharma, S.A.)|Projected earnings per share increase next year PYXS|Earnings growth forecast for next year CGEN (Compugen Ltd.)|Expected earnings per share trend next year IOBT|sutrobio.com - Earnings growth forecast for next year|Expected net earnings per share growth next year Werewolf Therapeutics, Inc.|Immix (IMMX) - Net earnings per share growth forecast for next year|ALX Oncology Holdings - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Cue Biopharma|Earnings growth forecast for next year pdsbiotech.com|Net earnings per share growth forecast for next year sonnetbio.com (SONN)|MAIA: Net earnings per share change forecast for next year|Liminatus Pharma Inc. - Expected earnings per share growth for next year|LAVA Therapeutics N.V. (LVTX) - Expected net earnings per share growth next year|NXTC - Net earnings per share growth forecast for next year|LPTX: Net earnings per share growth forecast for next year|Intensity Therapeutics (INTS) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Sensei Bio (SNSE)|TOVX (Theriva Biologics Inc) - Earnings growth forecast for next year|Gritstone bio (GRTS) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year KA|Consensus forecast of earnings per share growth for next year NexImmune Inc|Net earnings per share growth forecast for next year turnstonebio.com TSBX|Consensus forecast of earnings per share growth for next year Vaccinex Inc (VCNX)|HARP - Net earnings per share growth forecast for next year